A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

  • STATUS
    Recruiting
  • days left to enroll
    75
  • participants needed
    390
  • sponsor
    UCB Biopharma SRL
Updated on 5 September 2021
Investigator
UCB Cares
Primary Contact
Pa0011 50043 (0.0 mi away) Contact
+217 other location
corticosteroids
methotrexate
psoriasis
bimekizumab
steroidal anti-inflammatory drugs
tumor necrosis factor
NSAID
hydroxychloroquine
arthritis
tumor necrosis factor alpha
sulfasalazine
tumour necrosis
leflunomide
apremilast
rheumatoid factor
joints tender

Summary

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNF-IR) subjects with active Psoriatic Arthritis (PsA).

Details
Condition Psoriasis, PSORIATIC ARTHRITIS, Arthritis, Arthritis and Arthritic Pain, Psoriasis and Psoriatic Disorders, Arthritis and Arthritic Pain (Pediatric)
Treatment Placebo, Bimekizumab
Clinical Study IdentifierNCT03896581
SponsorUCB Biopharma SRL
Last Modified on5 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note